Regulation of gene expression in response to brain injury: Enhanced expression and alternative splicing of rat prosaposin (SGP-1) mRNA in injured brain

Journal of Neurotrauma

Volumn 20, Issue 8, 2003, Pages 755-765

  Hiraiwa, Masao ^a,c,d   Liu, Jian ^a   Lu, Ai Gang ^a   Wang, Cui Ying ^a   Misasi, Roberta ^b   Yamauchi, Toyoaki ^a   Hozumi, Isao ^c   Inuzuka, Takashi ^c   O'Brien, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c GIFU UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative splicing; Cerebral ischemia; Gene regulation; Neurotrauma; Neurotrophic factor; Prosaposin; Sphingolipid activator protein

Indexed keywords

MESSENGER RNA; NEUROTROPHIC FACTOR; PROSAPOSIN; SAPONIN; SPHINGOLIPID ACTIVATOR PROTEIN;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; EXON; GENE EXPRESSION REGULATION; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NERVE INJURY; NERVE REGENERATION; NONHUMAN; NORTHERN BLOTTING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; STAB WOUND; TISSUE SPECIFICITY;

EID: 0043023931     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/089771503767869980     Document Type: Article

References (56)

1. ASHWAL, S., TONE, B., TIAN, H.R., et al. (1998). Core and penumbral nitric oxide synthase activity during cerebral ischemia and reperfusion. Stroke 29, 1037-1047.
2. BRAISSANT, O., and WAHLI, W. (1998). A simplified in situ hybridization protocol using non-radioactively labeled probes to detect abundant and rare mRNAs on tissue sections. Biochemica 1, 10-16.
3. CAMPANA, W.M., HIRAIWA, M., and O'BRIEN, J.S. (1998). Prosaptide activates the mitogen-activated protein kinase pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J. 12, 307-314.
4. CHAMBERS, C.B., and MUMA, N.A. (1997). Tau mRNA isoforms following sciatic nerve axotomy with and without regeneration. Brain Res. Mol. Brain Res. 48, 115-124.
5. CHOMCZYNSKI, P., and SACCHI, N. (1987). Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
6. DOHERTY, P., MOOLENAAR, C.E., ASHTON, S.V., et al. (1992). The VASE exon downregulates the neurite growth-promoting activity of NCAM 140. Nature 356, 791-793.
7. FU, Q., CARSON, G.S., HIRAIWA, M., et al. (1994). Occurrence of prosaposin as a neuronal surface membrane component. J. Mol. Neurosci. 5, 59-67.
8. FUJITA, N., SUZUKI, K., VANIER, M.T., et al. (1996). Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 5, 711-725.
9. FUJITA, N., KEMPER, A., DUPREE, J., et al. (1998). The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination. J. Neurosci. 18, 1970-1978.
10. GILLEN, C., GLEICHMANN, M., SPREYER, P., et al. (1995). Differential expressed gene after peripheral nerve injury. J. Neurosci Res. 42, 159-171.
11. HARZER, K., PATON, B.C., POULOS, A., et al. (1989). Sphingolipid activator deficiency in a 16-week old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur. J. Pediatr. 149, 31-39.
12. HENSELER, M., KLEIN, A., GLOMBITZA, G.J., et al. (1996). Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system. J. Biol. Chem. 271, 8416-8423.
13. HIRAIWA, M., O'BRIEN, J.S., KISHIMOTO, Y., et al. (1993). Isolation, characterization, and proteolysis of human prosaposin, the precursor of saposins (sphingolipid activator proteins). Arch. Biochem. Biophys. 304, 110-116
14. HIRAIWA, M., MARTIN, B.M., KISHIMOTO, Y., et al. (1997a). Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. Arch. Biochem. Biophys. 341, 17-24.
15. HIRAIWA, M., TAYLOR, E.M., CAMPANA, W.M., et al. (1997b). Cell death prevention, MAP kinase stimulation, and enhanced sulfatide synthesis in Schwann cell and oligodendrocyte. Proc. Natl. Acad. Sci. USA 94, 4778-4781.
16. HIRAIWA, M., CAMPANA, W.M., MIZISIN, A.P., et al. (1999). Prosaposin: a myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 26, 353-360.
17. HOLTSCHMIDT, H., SANDHOFF, K., FURST, W., et al. (1991a). The organization of the gene for the human cerebroside sulfate activator protein. FEBS Lett. 280, 267-270.
18. HOLTSCHMIDT, H., SANDHOFF, K., KWON, H.Y., et al. (1991b). Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J. Biol. Chem. 266, 7556-7560.
19. HOPKINS, S.J., and ROTHWELL, N.J. (1995). Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci. 18, 83-88.
20. HOZUMI, I., CHIU, F.C., and NORTON, W.T. (1990). Biochemical and immunocytochemical changes in glial fibrillary acidic protein after stab wounds. Brain Res. 524, 64-71.
21. HOZUMI, I., HIRAIWA, M., INUZUKA, T., et al. (1999). Administration of prosaposin ameliorates spatial learning disturbance and reduces cavity formation following stab wounds in rat brain. Neurosci. Lett. 267, 73-76.
22. IGASE, K., TANAKA, J., KUMON, Y., et al. (1999). An 18-mer peptide fragment of prosaposin ameliorates place navigation disability, cortical infarction, and retrograde thalamic degeneration in rats with focal cerebral ischemia. J. Cereb. Blood Flow Metab. 19, 298-306.
23. KISHIMOTO, Y., HIRAIWA, M., and O'BRIEN, J.S. (1992). Saposins: structure, function, distribution, and molecular genetics J. Lipid Res. 33, 1255-1267.
24. KONDOH, K., HINENO, T., SANO, A., et al. (1991). Isolation and characterization of prosaposin from human milk. Biochem. Biophys. Res. Commun. 181, 286-292.
25. KOTANI, Y., MATSUDA, S., SAKANAKA, M., et al. (1996a). Prosaposin facilitates sciatic nerve regeneration in vivo. J. Neurochem. 66, 2019-2025.
26. KOTANI, Y., MATSUDA, S., WEN, T.-C., et al. (1996b). A hydrophilic peptide comprising 18 amino acid residues of the prosaposin sequence has neurotrophic activity in vitro and in vivo. J. Neurochem. 66, 2197-2200.
27. KREDA, S.M., FUJITA, N., and SUZUKI, K. (1994). Expression of sphingolipid activator protein gene in brain and systemic organs of developing mice. Dev. Neurosci. 16, 90-99.
28. KRETZ, K.A., CARSON, G.S., MORIMOTO, S., et al. (1990). Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. Proc. Natl. Acad. Sci. USA 87, 2541-2544.
29. LAMONTAGNE, S., and POTIER, M. (1994). Modulation of human saposin B sphingolipid-binding specificity by alternative splicing. A study with saposin B-derived synthetic peptides. J. Biol. Chem. 269, 20528-20532.
30. LEDERKREMER, G.Z., and LODISH, H.F. (1991). An alternatively spliced miniexon alters the subcellular fate of the human asialoglycoprotein receptor H2 subunit. Endoplasmic reticulum retention and degradation or cell surface expression. J. Biol. Chem. 266, 1237-1244.
31. LINDVALL, O., KOKAIA, Z., BENGZON, J., et al. (1994). Neurotrophins and brain insults. Trends Neurosci. 7, 490-496.
32. LIU, W.K., DICKSON, D.W., and YEN, S.H. (1993). Heterogeneity of tau proteins in Alzheimer's disease. Evidence for increased expression of an isoform and preferential distribution of a phosphorylated isoform in neurites. Am. J. Pathol. 142, 387-394.
33. LU, A.G., OTERO, D.A., HIRAIWA, M., et al. (2000). Neuroprotective effect of retro-inverso Prosaptide D5 on focal cerebral ischemia in rat. NeuroReport 11, 1791-1794.
34. + channel diversity in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 88, 3932-3936.
35. MADAR-SHAPIRO, L., PASMANIK-CHOR, M., VACCARO, A.M., et al. (1999). Importance of splicing for prosaposin sorting. Biochem. J. 337, 433-443.
36. MATSUDA, J., VANIER, M.T., SAITO, Y., et al. (2001). A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. Hum. Mol. Genet. 10, 1191-1199.
37. MERRILL, J.E., and BENVENISTE, E.N. (1996). Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 19, 331-338.
38. O'BRIEN, J.S., and KISHIMOTO, Y. (1991). Saposin proteins: structure, function, and role in human lysosoma storage disorders. FASEB J. 5, 301-308.
39. O'BRIEN, J.S., CARSON, G.S., SEO, H.-C., et al. (1994). Identification of prosaposin as a neurotrophic factor. Proc. Natl. Acad. Sci. USA 91, 9593-9596.
40. O'BRIEN, J.S., CARSON, G.S., SEO, H.-C., et al. (1995). Identification of the neurotrophic factor sequence of prosaposin. FASEB J. 9, 681-685.
41. OYA, Y., NAKAYASU, H., FUJITA, N., et al. (1998). Pathological study of mice with total deficiency of sphingolipid activator proteins (SAP knockout mice). Acta Neuropathol. 96, 29-40.
42. QI, X., QIN, W., SUN, Y., et al. (1996). Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions. J. Biol. Chem. 271, 6874-6880.
43. RAFI, M.A., ZHANG, X.L., DEGALA, G., et al. (1990). Detection of a point mutation in sphingolipid activator protein-1 mRNA in patients with a variant form of metachromatic leukodystrophy. Biochem. Biophys. Res. Commun. 166, 1017-1023.
44. RAMSHAW, A.L., and PARUMS, D.V. (1992). Combined immunohistochemical and immunofluorescence method to determine the phenotype of proliferating cell populations. J. Clin. Pathol. 45, 1015-1017.
45. ROTHWELL, N.J., and HOPKINS, S.J. (1995). Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci. 18, 130-136.
46. SANDHOFF, K., KOLTER, T., and VAN ECHTEN-DECKERT, G. (1998). Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins and the pathology of the cell. Ann. N. Y. Acad. Sci. 845, 139-151.
47. SANO, A., MATSUDA, S., WEN, T.-C., et al. (1994). Protection by prosaposin against ischemia-induced learning disability and neuronal loss. Biochem. Biophys. Res. Commun. 204, 994-1000.
48. SCHNABEL, D., SCHRODER, M., FURST, W., et al. (1992). Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the mutation codon of their common gene. J. Biol. Chem. 267, 3312-3315.
49. SUN, Y., WITTE, D.P., and GRABOWSKI, G.A. (1994). Developmental and tissue-specific expression of prosaposin mRNA in murine tissues. Amer. J. Pathol. 145, 1390-1398.
50. TANIUCHI, M., CLARK, H.B., and JOHNSON, E.M., JR. (1986). Induction of nerve growth factor receptor in Schwann cells after axotomy. Proc. Natl. Acad. Sci. USA 83, 4094-4098.
51. TANIUCHI, M., CLARK, H.B., SCHWEITZER, J.B., et al. (1988). Expression of nerve growth factor receptors by Schwann cells of axotomized peripheral nerves: ultrastructural location, suppression by axonal contact, and binding properties. J. Neurosci. 8, 664-681.
52. VOUYIOUKLIS, D.A., BARRIE, J.A., GRIFFITHS, I.R., et al. (2000). A proteolipid protein-specific pre-mRNA (Ppm-1) contains intron 3 and is up-regulated during myelination in the CNS. J. Neurochem. 74, 940-948.
53. WOODRUFF, R.H., and FRANKLIN, R.J. (1998). The expression of myelin basic protein exon 1 and exon 2 containing transcripts during myelination of the neonatal rat spinal cord - an in situ hybridization study. J. Neurocytol. 27, 683-693.
54. YOKOTA, N., UCHIJIMA, M., NISHIZAWA, S., et al. (2001). Identification of differential expressed genes in rat hippocampus after transient global cerebral ischemia using subtractive cDNA cloning based on polymerase chain reaction. Stroke 32, 168-174.
55. ZHANG, X.L., RAFI, M.A., DEGALA, G., et al. (1990). The mechanism for a 33-nucleotide insertion in mRNA causing sphingolipid activator protein (SAP-1)-deficient metachromatic leukodystrophy. Hum. Genet. 87,211-215.
56. ZHANG, X.L., RAFI, M.A., DEGALA, G., et al. (1990). Insertion in the mRNA of a metachromatic leukodystrophy patient with sphingolipid activator protein-1 deficiency. Proc. Natl. Acad. Sci. USA 87, 1426-1430.